[Ip-health] Millions Spent On Never-Reviewed Drugs - FDA Says It's Trying To Squeeze Unapproved Drugs From Market

Mon Nov 24 05:43:45 2008

NewsNet5.com
Related To Story
Pills, medication
Snip:
The AP checked the medications against FDA databases, using agency
guidelines to determine if they were unapproved. The FDA says there may
be thousands of such drugs on the market.

----
Millions Spent On Never-Reviewed Drugs
FDA Says It's Trying To Squeeze Unapproved Drugs From Market

POSTED: 12:34 pm EST November 23, 2008

WASHINGTON -- Taxpayers have shelled out at least $200 million since
2004 for medications that have never been reviewed by the government for
safety and effectiveness but are still covered under Medicaid, an
Associated Press analysis of federal data has found. Millions of private
patients are taking such drugs, as well.

The availability of unapproved prescription drugs to the public may
create a dangerous false sense of security. Dozens of deaths have been
linked to them.

The medications date back decades, before the Food and Drug
Administration tightened its review of drugs in the early 1960s. The FDA
says it is trying to squeeze them from the market, but conflicting
federal laws allow the Medicaid health program for low-income people to
pay for them.

The AP analysis found that Medicaid paid nearly $198 million from 2004
to 2007 for more than 100 unapproved drugs, mostly for common conditions
such as colds and pain. Data for 2008 were not available but unapproved
drugs still are being sold. The AP checked the medications against FDA
databases, using agency guidelines to determine if they were unapproved.
The FDA says there may be thousands of such drugs on the market.

Medicaid officials acknowledge the problem, but say they need help from
Congress to fix it. The FDA and Medicaid are part of the Health and
Human Services Department, but the FDA has yet to compile a master list
of unapproved drugs, and Medicaid -- which may be the biggest purchaser
-- keeps paying.

"I think this is something we ought to look at very hard, and we ought
to fix it," said Medicaid chief Herb Kuhn. "It raises a whole set of
questions, not only in terms of safety, but in the efficiency of the
program -- to make sure we are getting the right set of services for
beneficiaries."

At a time when families, businesses and government are struggling with
health care costs and 46 million people are uninsured, payments for
questionable medications amount to an unplugged leak in the system.

Sen. Charles Grassley, R-Iowa, has asked the HHS inspector general to
investigate.

That unapproved prescription drugs can be sold in the United States
surprises even doctors and pharmacists. But the FDA estimates they
account for 2 percent of all prescriptions filled by U.S. pharmacies,
about 72 million scripts a year. Private insurance plans also cover them.

The roots of the problem go back in time, tangled in layers of legalese.

It wasn't until 1962 that Congress ordered the FDA to review all new
medications for effectiveness. Thousands of drugs already on the market
were also supposed to be evaluated. But some manufacturers claimed their
medications were "grandfathered" under earlier laws, and even under the
1962 bill.

Then, in the early 1980s, a safety scandal erupted over one of those
medications. E-Ferol, a high potency vitamin E injection, was linked to
serious reactions in some 100 premature babies, 40 of whom died.

In response, the FDA started a program to weed out drugs it had never
reviewed scientifically. Yet some medications continued to escape scrutiny.

Sometimes, the medications do not help patients. In other cases, the FDA
says, they have made people sicker, maybe even killed them. This year,
for example, the FDA banned injectable versions of a gout drug called
colchicine after receiving reports of 23 deaths. Investigators found the
unapproved drug had a very narrow margin of safety, and patients easily
could receive a toxic dose leading to complications such as organ failure.

Critics say the FDA's case-by-case enforcement approach is not working.

"The FDA does not appear to have a systematic mechanism to report these
drugs out," said Jon Glaudemans, senior vice president of Avalere
Health, a health care industry information company, "and there doesn't
seem to be a systematic process by which health insurance programs can
validate their status. And everyone is pointing the finger at someone
else as to why we can't get there."

In most cases, doctors, pharmacists and patients are not aware the drugs
are unapproved.

"Over the years, they have become fully entrenched in the system," said
Patti Manolakis, a Charlotte, N.C., pharmacist who has studied the
issue. Only a few unapproved drugs are truly essential and should remain
on the market, she added.

Tackling the problem is made harder by confusing -- and sometimes
conflicting -- laws, regulations and responsibilities that pertain to
different government agencies.

Medicaid officials said their program, which serves the poor and
disabled, is allowed to pay for unapproved drugs until the FDA orders a
specific medication off the market. But that can take years.

Compare that with Medicare, the health care program for older people.

Medicare's prescription program is not supposed to cover unapproved
drugs. Medicare has purged hundreds of such medications from its
coverage lists, but continues to find others.

It might be easier to sort things out if the FDA compiled a master list
of unapproved drugs, but the agency hasn't. FDA officials say that would
be difficult because many manufacturers do not list unapproved products
with the agency. Yet, the AP found many that were listed -- a possible
starting point for a list.

Among the drugs the AP's research identified were Carbofed, for colds
and flu; Hylira, a dry skin ointment; Andehist, a decongestant, and ICAR
Prenatal, a vitamin tablet. Medicaid data show the program paid $7.3
million for Carbofed products from 2004 to 2007; $146,000 for Hylira;
$4.8 million for Andehist products, and $900,000 for ICAR.

Grassley said the system is failing taxpayers and consumers.

"The problem I see is bureaucrats don't want to make a decision,"
Grassley said. "There is no reason why this should be such a house of
mirrors when so much public money is being spent." Grassley is
considering introducing legislation to ensure that consumers are told
when a medication is unapproved.

FDA officials say they tell Medicaid and Medicare when the agency moves
to ban an unapproved drug, so the programs can stop paying.

"The situation is complicated by the fact that Medicaid and Medicare
have a different regulatory regime than FDA does," said FDA compliance
lawyer Michael Levy. "There are products that we may consider to be
illegally marketed that could be legally reimbursed under their law."

The FDA began its latest crackdown on unapproved drugs two years ago and
has taken action against nine types of medications and dozens of
companies. Typically, the agency orders manufacturers to stop making and
shipping drugs, and it also has seized millions of dollars' worth of
medications. But federal law does not provide fines for selling
unapproved drugs, and criminal prosecutions are rare.

Some manufacturers of unapproved drugs say their products predate FDA
regulation and are "grandfathered in."

"These are drugs that don't require an FDA approval," said Bill Peters,
chief financial officer of Hi-Tech Pharmacal in Amityville, N.Y. "These
are products with active ingredients that have been on the market for a
long time." The company is moving away from older products, Peters said,
and its new market offerings are FDA-approved.

Levy said the FDA is skeptical that any drugs now being sold are
entitled to "grandfather" status. To qualify, they would have to be
identical to medications sold decades ago in formulation and other
important aspects.

The agency is targeting drugs linked to fraud, ones that do not work
and, above all, those with safety risks. While the crackdown has helped,
it does not appear to have solved the problem.

The gout drug banned by the FDA this February is not the only recent
case involving safety problems.

Last year, the FDA banned unapproved cough medicines containing
hydrocodone, a potent narcotic. Some had directions for medicating
children as young as age 2, although no hydrocodone cough products have
been shown to be safe and effective for children under 6.

In a 2006 case, the agency received 21 reports of children younger than
2 who died after taking unapproved cold and allergy medications
containing carbinoxamine, an allergy drug that also acts as a powerful
sedative. Regulators banned all products that contained carbinoxamine in
combination with other cold medicines.

"We as Americans have a belief that all the prescription drugs that are
available to us have been reviewed and approved by the FDA," said
Manolakis, the pharmacist. "I think the presence of these drugs shows we
have a false sense of security."

http://www.newsnet5.com/print/18044086/detail.html